FDA Naloxone OTC Pattern Labels Confirmed in CONFER Study – Rose Sheet

[ad_1]

1. The Naloxone OTC model labels of the FDA have been confirmed in the Rose study of the CONFER study
2. The FDA is trying to make it easier for pharmaceutical companies to provide OTC TIME opioid overdose antidote
3. FDA moves to accelerated treatment of over-the-counter naloxone for the treatment of Medscape opioid overdoses
4. FDA gives Pharma a boost to develop the Bloomberg antidote for over-the-counter opioid overdose
5. FDA paves the way to increase access and reduce the cost of life-saving opioid overdose drug, CNBC
6. View full coverage on Google News

[ad_2]
Source link